Investor Relations

About us

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, veterinarians and farmers by providing solutions to help them maintain and enhance the health of their animals and produce healthy, affordable food while using fewer natural resources. We sell more than 1,625 product presentations in over 80 countries to approximately 3,725 customers. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, swine and cattle integrators or through commercial animal feed manufacturers, wholesalers and distributors.

We are investing resources to develop future products for the companion animal sector.

In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries. We sell performance products directly to customers in the aforementioned industries.

Our Class A common stock trades on the Nasdaq Stock Market (“Nasdaq”) under the trading symbol “PAHC.” Our Class B common stock is not listed or traded on any stock exchange. We are a Delaware corporation.

Phibro Animal Health Corporation reported net sales of $833 million for the fiscal year ended June 30, 2021. Our approximate 1,725 employees are proud to manufacture and market our products globally. We are headquartered in Teaneck, New Jersey, and have offices across the United States and around the world.


Featured Presentation

All Presentations

Investor Events

All Events

On August 27, 2020, the Company hosted a conference call and live webcast to discuss its financial results for the quarter and fiscal year ended June 30, 2020 with investors and analysts (the “Earnings Call”). At approximately 38:07 during the Earnings Call recording and page 12 of the Earnings Call transcript, in response to a question from a participant, we stated that we have been selling our products containing virginiamycin in Brazil under regulatory approvals containing therapeutic claims for approximately one year. More accurately, we are more than one year into a transition period established by the regulatory authorities in Brazil to cease using growth promotion claims for certain products, including products containing virginiamycin. We are in the process of seeking therapeutic claims for these products in Brazil. We expect our ability to sell these products under the current growth promotion claims will continue during this transition period.

Press Releases

All Press Releases